Monopar Therapeutics (MNPR): Cash & Equivalents
$61.83M
As of 2025-12-31
$52.76M
As of 2026-06-30
+96.2%
3-year compound annual growth
+29.9%
5-year compound annual growth
| Period ended | Cash & Equivalents | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $61.83M | +35.0% | 2026-03-27, Balance as of period end |
| 2024-12-31 | $45.82M | +530.6% | 2026-03-27, Balance as of period end |
| 2023-12-31 | $7.27M | -11.2% | 2025-03-31, Balance as of period end |
| 2022-12-31 | $8.19M | -59.7% | 2024-03-28, Balance as of period end |
| 2021-12-31 | $20.30M | +21.3% | 2023-03-23, Balance as of period end |
| 2020-12-31 | $16.74M | +26.7% | 2022-03-24, Balance as of period end |
| 2019-12-31 | $13.21M | +91.7% | 2021-03-25, Balance as of period end |
| 2018-12-31 | $6.89M | -23.3% | 2020-03-27, Balance as of period end |
| 2017-12-31 | $8.98M | +333.4% | 2019-02-26, Balance as of period end |
| 2016-12-31 | $2.07M | n/a | 2018-03-26, Balance as of period end |
Cash & Equivalents at similar companies
| Company | Year ended | Cash & Equivalents | Change YoY |
|---|---|---|---|
| Monopar Therapeutics (MNPR) | 2025-12-31 | $61.83M | +35.0% |
| Abbott Laboratories (ABT) | 2025-12-31 | $8.52B | +11.9% |
| Bristol Myers Squibb Co (BMY) | 2025-12-31 | $10.21B | -1.3% |
| TherapeuticsMD, Inc. (TXMD) | 2024-12-31 | $5.06M | +16.9% |
| Eli Lilly & Co (LLY) | 2025-12-31 | $7.27B | +122.4% |
| Pfizer Inc (PFE) | 2025-12-31 | $1.14B | +9.5% |
| Johnson & Johnson (JNJ) | 2025-12-28 | $19.71B | -18.2% |
| Nature's Sunshine Products Inc (NATR) | 2025-12-31 | $93.89M | +10.9% |
| Merck & Co., Inc. (MRK) | 2025-12-31 | $14.56B | +10.0% |
Compare MNPR, ABT, BMY, TXMD side by side · Screen every company in Pharmaceutical Preparations ↗